Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
This partnership has led to a 10% boost in delivery speed
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Subscribe To Our Newsletter & Stay Updated
